78 results
Page 2 of 4
8-K
EX-99.2
ubzo1852dhyrtyqj5o
12 May 21
Diffusion Pharmaceuticals Reports First Quarter Financial Results
7:30am
424B5
42o 5korx7dr2zehg5
17 Feb 21
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
grssk3 xyu1dn49gws
16 Feb 21
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
8:10am
424B5
9m7u 6py2nx7ariwm0yl
11 Feb 21
Prospectus supplement for primary offering
5:28pm
8-K
EX-10.1
tyht f0luz193zfp
20 Oct 20
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
5:30pm
424B2
9pq3ra e2
2 Oct 20
Prospectus for primary offering
4:16pm
8-K
EX-10.1
10agesjbtor
25 Sep 20
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
4:57pm
8-K
EX-99.1
35yay49 wppxh6oieh
10 Sep 20
Other Events
4:39pm
8-K
EX-10.2
q2mwxd n2n
9 Sep 20
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
9:30am
8-K
EX-99.1
tmu90fg7af2dr
29 Jul 20
Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC
8:14am
8-K
EX-99.1
4oa3wu2ewhdajp8ze 6z
7 Jul 20
Phase 1b dosing expected to begin this month
4:38pm
8-K
EX-99.1
2t1qtugfe7ugf3m2std
12 Jun 20
Dosing expected to begin in Q2 2020 with first data in Q3 2020
12:18pm
424B3
b0b2c0bvyg
8 Jun 20
Prospectus supplement
4:48pm
8-K
EX-99.1
dlpox
26 May 20
Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program
4:45pm
8-K
EX-99.1
ynm3u
20 May 20
Other Events
5:27pm